NCT04072237View on ClinicalTrials.gov

Study of Coagulation Faction VIIa Variant Marzeptacog Alfa (Activated) in Adult Subjects With Hemophilia

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

September 24, 2019

Primary Completion Date

April 30, 2020

Study Completion Date

June 17, 2020

Conditions
Hemophilia AHemophilia BHemophilia A With InhibitorHemophilia B With InhibitorHemophilia A Without InhibitorHemophilia B Without Inhibitor
Interventions
BIOLOGICAL

MarzAA (marzeptacog alfa [activated])

Single intravenous dose and ascending doses of subcutaneous injection of MarzAA (Coagulation Faction VIIa Variant)

Trial Locations (5)

Unknown

"Medical Center Hippocrates - N", Plovdiv

Specialized Hospital for Active Treatment of Hematological Diseases, Sofia

Kirov Research Institute of Hematology and Blood Transfusion, Kirov

National Medical Hematology Research Center, Moscow

Municipal Policlinic # 37, City Center for Hemophilia Treatment, Saint Petersburg

Sponsors
All Listed Sponsors
lead

Catalyst Biosciences

INDUSTRY